BMS registers Phase 1/2a trial of BMS-986548 in KRAS-altered solid tumorsNov 16Trial updateBristol Myers Squibb
Seagen/Pfizer's MOUNTAINEER-03 trial for HER2+ colorectal cancer remains active, not recruitingNov 16Trial updatebevacizumabPfizer
Parabilis reports Q3 2026 results, aligns with FDA on desmoid Phase 3 designNov 12Quarterly updateParabilis Medicines, Inc.
Boehringer posts BI 1291583 results; registers obrixtamig rollover and four more trialsNov 12Weekly roundup, 7 itemsBoehringer IngelheimzongertinibUpdated
FDA's traditional approval of encorafenib followed earlier accelerated approval in same indicationNov 9Regulatory decisionencorafenibPfizerUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Roche group registers Phase III UC trial, GA-AMD study; AD extension stays activeOct 30Weekly roundup, 7 itemsafimkibartastegolimab
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Adlai Nortye signs trial deals with Lilly, Merck KGaA for AN4035-cetuximab studyOct 15PartnershipAdlai Nortye Group Ltd.cetuximab
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies updateOct 9Weekly roundup, 8 itemsinclisiraniptacopanUpdated
Sanofi posts SAR444881 results; adds two rilzabrutinib trials and RSV AI studyOct 2Weekly roundup, 5 itemsrilzabrutinibSanofiUpdated
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on recordOct 2Weekly roundup, 8 itemsdolutegravir sodium and lamivudinedoravirineUpdated
Lilly registers three new early trials: olomorasib in colorectal cancer, two obesity studiesSep 11Weekly roundup, 3 itemsEli Lillyeloralintide
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
BeOne Medicines registers Phase 1a/1b trial of RAS inhibitor BG-85738 in solid tumorsAug 4Trial updateBeiGenetislelizumab
Adlai Nortye clears Australian regulatory steps for AN4035 phase I trialAug 3Regulatory decisionAdlai Nortye Group Ltd.
Ascentage Pharma names new Chief Business Officer and Chief Commercial OfficerAug 3PeopleAscentage Pharma Group International
Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML studyJul 30Weekly roundup, 3 itemsBristol Myers Squibbiberdomide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib